Bone Biologics director receives 114K stock options

Q: How many options did BBLG director Bruce Stroever receive, and at what exercise price?

Bruce Stroever received 113,896 non-employee stock options with an exercise price of $0.50 per share on September 28, 2026.

The award is under the Bone Biologics Corporation 2015 Equity Incentive Plan and vests in four equal quarterly installments, except as otherwise provided in the award notice.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bone Biologics Corp director Bruce Stroever received a grant of 113,896 non-employee stock options on September 28, 2026, with an exercise price of $0.50 per share and expiration on September 28, 2036. A separate direct option position covers 10,483 underlying shares at $5.28 per share and expires June 4, 2035.

Insider Trade Summary

Grant/Award: 113,896 shares

Grant/Award 7 txns

Insider Stroever Bruce

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Employee Stock Option ^F1	113,896	$0.00	$0.00
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--

Holdings After Transaction: Non-Employee Stock Option — 131,321 contracts for 17,425 underlying shares (Direct)

Footnotes (2)

F1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.
F2. This option is fully exercisable as of the date of this report.

Key Figures

Non-employee stock options granted: 113,896 options Exercise price: $0.50 per share Expiration date: September 28, 2036 +3 more

6 metrics

Non-employee stock options granted 113,896 options September 28, 2026

Exercise price $0.50 per share New option grant

Expiration date September 28, 2036 New option grant

Existing option underlying shares 10,483 shares at $5.28 per share Expires June 4, 2035

Existing option underlying shares 5,119 shares at $10.38 per share Expires September 17, 2034

Vesting installments Four equal quarterly installments New option grant, except as otherwise provided in the award notice

Key Terms

Non-Employee Stock Option, Rule 16b-3, fully exercisable

3 terms

Non-Employee Stock Option technical

"This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan"

Rule 16b-3 regulatory

"in a transaction exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

fully exercisable technical

"This option is fully exercisable as of the date of this report"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did BBLG director Bruce Stroever receive, and at what exercise price?

Bruce Stroever received 113,896 non-employee stock options with an exercise price of $0.50 per share on September 28, 2026.

How does Bruce Stroever's BBLG option award vest?

The options were granted under the Bone Biologics Corporation 2015 Equity Incentive Plan and vest in four equal quarterly installments, except as otherwise provided in the award notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/30/2026 - 05:07 PM Accepted by SEC EDGAR 09/30/2026 - 05:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stroever Bruce

(Last)

(First)

(Middle)

C/O BONE BIOLOGICS CORP

2 BURLINGTON WOODS DR. SUITE 100

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bone Biologics Corp [ BBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Employee Stock Option	$0.5	09/28/2026		A		113,896		⁽¹⁾	09/28/2036	Common Stock	113,896	$0	113,896	D
Non-Employee Stock Option	$5.28							⁽²⁾	06/04/2035	Common Stock	10,483		10,483	D
Non-Employee Stock Option	$10.38							⁽²⁾	09/17/2034	Common Stock	5,119		5,119	D
Non-Employee Stock Option	$30.72							⁽²⁾	09/13/2033	Common Stock	1,787		1,787	D
Non-Employee Stock Option	$2,323.58							⁽²⁾	08/23/2027	Common Stock	26		26	D
Non-Employee Stock Option	$5,068.8							⁽²⁾	01/01/2032	Common Stock	7		7	D
Non-Employee Stock Option	$7,560							⁽²⁾	10/26/2031	Common Stock	3		3	D

Explanation of Responses:

1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

2. This option is fully exercisable as of the date of this report.

	/s/ Bruce Stroever	09/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR